NOT FOR DISTRIBUTION
Header cover image

Market Cap

NZ$7.2b

Last Updated

2021/04/18 07:01 UTC

Data Sources

Company Financials +

Executive Summary

Ryman Healthcare Limited develops, owns, and operates integrated retirement villages, rest homes, and hospitals for the elderly in New Zealand and Australia. More Details


Snowflake Analysis

Average dividend payer with moderate growth potential.


Similar Companies

Share Price & News

How has Ryman Healthcare's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: RYM is not significantly more volatile than the rest of NZ stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: RYM's weekly volatility (4%) has been stable over the past year.


Market Performance


7 Day Return

-4.2%

RYM

-0.9%

NZ Healthcare

1.2%

NZ Market


1 Year Return

17.6%

RYM

29.9%

NZ Healthcare

19.3%

NZ Market

Return vs Industry: RYM underperformed the NZ Healthcare industry which returned 29.9% over the past year.

Return vs Market: RYM underperformed the NZ Market which returned 19.2% over the past year.


Shareholder returns

RYMIndustryMarket
7 Day-4.2%-0.9%1.2%
30 Day-7.1%-3.8%0.9%
90 Day-1.9%0.6%-1.9%
1 Year19.5%17.6%32.8%29.9%22.6%19.3%
3 Year45.9%38.5%63.9%52.4%50.6%33.5%
5 Year79.6%64.1%49.7%30.3%83.7%42.4%

Long-Term Price Volatility Vs. Market

How volatile is Ryman Healthcare's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Ryman Healthcare undervalued compared to its fair value and its price relative to the market?

25.05x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: RYM (NZ$14.47) is trading above our estimate of fair value (NZ$6.37)

Significantly Below Fair Value: RYM is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: RYM is poor value based on its PE Ratio (25x) compared to the NZ Healthcare industry average (24.7x).

PE vs Market: RYM is poor value based on its PE Ratio (25x) compared to the NZ market (22.3x).


Price to Earnings Growth Ratio

PEG Ratio: RYM is poor value based on its PEG Ratio (1.7x)


Price to Book Ratio

PB vs Industry: RYM's PB Ratio (2.9x) is in line with the NZ Healthcare industry average.


Future Growth

How is Ryman Healthcare forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

15.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: RYM's forecast earnings growth (15% per year) is above the savings rate (2.3%).

Earnings vs Market: RYM's earnings (15% per year) are forecast to grow faster than the NZ market (10.2% per year).

High Growth Earnings: RYM's earnings are forecast to grow, but not significantly.

Revenue vs Market: RYM's revenue (11.3% per year) is forecast to grow faster than the NZ market (6.9% per year).

High Growth Revenue: RYM's revenue (11.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: RYM's Return on Equity is forecast to be low in 3 years time (16.5%).


Past Performance

How has Ryman Healthcare performed over the past 5 years?

-1.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: RYM has a large one-off gain of NZ$165.5M impacting its September 30 2020 financial results.

Growing Profit Margin: RYM's current net profit margins (66%) are lower than last year (85.5%).


Past Earnings Growth Analysis

Earnings Trend: RYM's earnings have declined by 1.3% per year over the past 5 years.

Accelerating Growth: RYM's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: RYM had negative earnings growth (-16.1%) over the past year, making it difficult to compare to the Healthcare industry average (14%).


Return on Equity

High ROE: RYM's Return on Equity (11.8%) is considered low.


Financial Health

How is Ryman Healthcare's financial position?


Financial Position Analysis

Short Term Liabilities: RYM's short term assets (NZ$514.2M) exceed its short term liabilities (NZ$234.4M).

Long Term Liabilities: RYM's short term assets (NZ$514.2M) do not cover its long term liabilities (NZ$5.6B).


Debt to Equity History and Analysis

Debt Level: RYM's debt to equity ratio (87.7%) is considered high.

Reducing Debt: RYM's debt to equity ratio has increased from 42.2% to 87.7% over the past 5 years.

Debt Coverage: RYM's debt is not well covered by operating cash flow (13.5%).

Interest Coverage: RYM's interest payments on its debt are not well covered by EBIT (2.2x coverage).


Balance Sheet


Dividend

What is Ryman Healthcare current dividend yield, its reliability and sustainability?

1.67%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: RYM's dividend (1.67%) isn’t notable compared to the bottom 25% of dividend payers in the NZ market (2.41%).

High Dividend: RYM's dividend (1.67%) is low compared to the top 25% of dividend payers in the NZ market (4.59%).


Stability and Growth of Payments

Stable Dividend: RYM's dividends per share have been stable in the past 10 years.

Growing Dividend: RYM's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (37.2%), RYM's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: RYM's dividends in 3 years are forecast to be well covered by earnings (50% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

Gordon MacLeod

3.75yrs

Tenure

NZ$1,356,641

Compensation

Mr. Gordon MacLeod has been the Chief Executive Officer since July 1, 2017 of Ryman Healthcare Limited since October 26, 2006 and serves as its Secretary and served as its Deputy Chief Executive and Chief ...


CEO Compensation Analysis

Compensation vs Market: Gordon's total compensation ($USD967.85K) is below average for companies of similar size in the NZ market ($USD1.57M).

Compensation vs Earnings: Gordon's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: RYM's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

Experienced Board: RYM's board of directors are considered experienced (3.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: RYM insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Ryman Healthcare Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Ryman Healthcare Limited
  • Ticker: RYM
  • Exchange: NZSE
  • Founded: 1984
  • Industry: Health Care Facilities
  • Sector: Healthcare
  • Market Cap: NZ$7.235b
  • Shares outstanding: 497.29m
  • Website: https://www.rymanhealthcare.co.nz

Number of Employees


Location

  • Ryman Healthcare Limited
  • Airport Business Park
  • 92 Russley Road
  • Christchurch
  • 8042
  • New Zealand

Listings


Biography

Ryman Healthcare Limited develops, owns, and operates integrated retirement villages, rest homes, and hospitals for the elderly in New Zealand and Australia. Its villages offer a range of retirement living...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/18 07:01
End of Day Share Price2021/04/16 00:00
Earnings2020/09/30
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.